Xspray Pharma Q3 2022: A Pivotal Year Ahead - Redeye

Redeye leaves its comments on Xspray Pharma’s Q3 2022 report. Today’s report confirms that the pivotal trial for XS003 is now ongoing, and some news on the XS008 timeline was revealed. We maintain our positive take on the case and expect 2023 to materialize a pivotal year for Xspray.

Länk till analysen i sin helhet: https://www.redeye.se/research/862075/xspray-pharma-q3-2022-a-pivotal-year-ahead?utm_source=finwire&utm_medium=RSS